Linked immunotherapeutic agonists that costimulate multiple pathways
AssigneeUniversity of Connecticut
InventorsANTHONY T. VELLA, ADAM J. ADLER
Life of this patent
Estimating the term…
Abstract
Described herein are modified immunotherapeutic agents including a first monoclonal antibody covalently linked to a second monoclonal antibody generating a single new immunotherapeutic agent. The first and second monoclonal antibodies stimulate different anti-tumor pathways. Advantageously, the modified single immunotherapeutic agent is capable of activating both anti-tumor pathways. Also included herein are methods of treating cancer with the modified immunotherapeutic agents.
Claims16
A modified immunotherapeutic agent comprising
- a first monoclonal antibody covalently linked to a second monoclonal antibody,
- wherein the first and second monoclonal antibodies stimulate different anti-tumor pathways, and wherein the modified immunotherapeutic agent is capable of activating both anti-tumor pathways.
The modified immunotherapeutic agent of claim, wherein the first and second monoclonal antibodies are F(ab′)2 fragments without Fc domains, and wherein the F(ab′)2 fragments are covalently linked using click chemistry.
Dependencies are inferred from the claim text.